Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Oct;56(4):465–469. doi: 10.1038/bjc.1987.225

3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.

R E Coleman 1, R D Rubens 1
PMCID: PMC2001821  PMID: 3689664

Abstract

The effect of a single dose of APD on hypercalcaemia has been studied in advanced breast cancer. Twenty-five patients were rehydrated intravenously for 48 h. Twenty-three remained hypercalcaemic and received 5-15 mg APD as a 2 h infusion. Eighteen patients achieved normocalcaemia, 15 after a dose of less than or equal to 15 mg. One patient died within 24 h from rapidly advancing disease and 4 remained hypercalcaemic. Urinary calcium excretion increased during rehydration as glomerular function improved and tubular reabsorption of calcium fell. After APD, calcium excretion fell to normal in 22/24 patients reflecting inhibition of bone resorption. Hydroxyproline excretion remained high. The effect of a single dose of APD on hypercalcaemia lasted a median of 11 days (range 7-17). Transient fever occurred in 2 patients, but there were no other side effects. The possibility of long-term control of osteolysis using a 2 weekly schedule of APD administration is now being studied.

Full text

PDF
465

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Body J. J. Cancer hypercalcemia: recent advances in understanding and treatment. Eur J Cancer Clin Oncol. 1984 Jul;20(7):865–869. doi: 10.1016/0277-5379(84)90155-x. [DOI] [PubMed] [Google Scholar]
  2. Cantwell B. M., Harris A. L. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer. Br Med J (Clin Res Ed) 1987 Feb 21;294(6570):467–469. doi: 10.1136/bmj.294.6570.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cleary J., Saunders R. A. A simplified procedure for the measurement of total hydroxyproline in urine. Clin Chim Acta. 1974 Dec 17;57(3):217–223. doi: 10.1016/0009-8981(74)90400-8. [DOI] [PubMed] [Google Scholar]
  4. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987 Jan;55(1):61–66. doi: 10.1038/bjc.1987.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coombes R. C., Dady P., Parsons C., McCready V. R., Ford H. T., Gazet J. C., Powles T. J. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 1983 Aug 15;52(4):610–614. doi: 10.1002/1097-0142(19830815)52:4<610::aid-cncr2820520406>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  6. Elomaa I., Blomqvist C., Gröhn P., Porkka L., Kairento A. L., Selander K., Lamberg-Allardt C., Holmström T. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet. 1983 Jan 22;1(8317):146–149. doi: 10.1016/s0140-6736(83)92755-1. [DOI] [PubMed] [Google Scholar]
  7. Elte J. W., Bijvoet O. L., Cleton F. J., van Oosterom A. T., Sleeboom H. P. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol. 1986 Apr;22(4):493–500. doi: 10.1016/0277-5379(86)90117-3. [DOI] [PubMed] [Google Scholar]
  8. Fisken R. A., Heath D. A., Bold A. M. Hypercalcaemia--a hospital survey. Q J Med. 1980 Autumn;49(196):405–418. [PubMed] [Google Scholar]
  9. Galasko C. S. Mechanisms of bone destruction in the development of skeletal metastases. Nature. 1976 Oct 7;263(5577):507–508. doi: 10.1038/263507a0. [DOI] [PubMed] [Google Scholar]
  10. Grant C. S., Hoare S. A., Millis R. R., Hayward J. L., Wang D. Y. Urinary hydroxyproline and prognosis in human breast cancer. Br J Surg. 1984 Feb;71(2):105–108. doi: 10.1002/bjs.1800710208. [DOI] [PubMed] [Google Scholar]
  11. Jung A. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy. Am J Med. 1982 Feb;72(2):221–226. doi: 10.1016/0002-9343(82)90813-0. [DOI] [PubMed] [Google Scholar]
  12. Kanis J. A., Percival R. C., Yates A. J., Urwin G. H., Hamdy N. A. Effects of diphosphonates in hypercalcaemia due to neoplasia. Lancet. 1986 Mar 15;1(8481):615–616. doi: 10.1016/s0140-6736(86)92834-5. [DOI] [PubMed] [Google Scholar]
  13. Legha S. S., Powell K., Buzdar A. U., Blumenschein G. R. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981 Jun 15;47(12):2803–2806. doi: 10.1002/1097-0142(19810615)47:12<2803::aid-cncr2820471208>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  14. Mundy G. R., Ibbotson K. J., D'Souza S. M. Tumor products and the hypercalcemia of malignancy. J Clin Invest. 1985 Aug;76(2):391–394. doi: 10.1172/JCI111984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mundy G. R. Pathogenesis of hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1985 Dec;23(6):705–714. doi: 10.1111/j.1365-2265.1985.tb01132.x. [DOI] [PubMed] [Google Scholar]
  16. Orrell D. H. Albumin as an aid to the interpretation of serum calcium. Clin Chim Acta. 1971 Dec;35(2):483–489. doi: 10.1016/0009-8981(71)90224-5. [DOI] [PubMed] [Google Scholar]
  17. Peacock M., Robertson W. G., Nordin B. E. Relation between serum and urinary calcium with particular reference to parathyroid activity. Lancet. 1969 Feb 22;1(7591):384–386. doi: 10.1016/s0140-6736(69)91353-1. [DOI] [PubMed] [Google Scholar]
  18. Percival R. C., Paterson A. D., Yates A. J., Beard D. J., Douglas D. L., Neal F. E., Russell R. G., Kanis J. A. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer. 1985 May;51(5):665–669. doi: 10.1038/bjc.1985.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Percival R. C., Yates A. J., Gray R. E., Galloway J., Rogers K., Neal F. E., Kanis J. A. Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) 1985 Sep 21;291(6498):776–779. doi: 10.1136/bmj.291.6498.776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Percival R. C., Yates A. J., Gray R. E., Neal F. E., Forrest A. R., Kanis J. A. Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) 1984 Aug 4;289(6440):287–287. doi: 10.1136/bmj.289.6440.287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ralston S. H., Alzaid A. A., Gardner M. D., Boyle I. T. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Br Med J (Clin Res Ed) 1986 Jun 14;292(6535):1549–1550. doi: 10.1136/bmj.292.6535.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ralston S. H., Fogelman I., Gardiner M. D., Boyle I. T. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 1984 May 12;288(6428):1405–1408. doi: 10.1136/bmj.288.6428.1405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ralston S. H., Gardner M. D., Dryburgh F. J., Jenkins A. S., Cowan R. A., Boyle I. T. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet. 1985 Oct 26;2(8461):907–910. doi: 10.1016/s0140-6736(85)90848-7. [DOI] [PubMed] [Google Scholar]
  24. Reitsma P. H., Bijvoet O. L., Verlinden-Ooms H., van der Wee-Pals L. J. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int. 1980;32(2):145–157. doi: 10.1007/BF02408534. [DOI] [PubMed] [Google Scholar]
  25. Sleeboom H. P., Bijvoet O. L., van Oosterom A. T., Gleed J. H., O'Riordan J. L. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia. Lancet. 1983 Jul 30;2(8344):239–243. doi: 10.1016/s0140-6736(83)90231-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES